Comparing a new eye injection to standard treatment for diabetic eye swelling
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes with a recent A1c level of 12% or lower
- Your vision loss in the study eye is mainly due to diabetic macular edema (DME)
- If you haven't treated DME before, you were diagnosed within the last 9 months; if you have had treatment, it started no more than 3 years ago
- You haven't had kidney failure requiring dialysis or a transplant, and you're not expected to need it soon
- You haven't had a stroke or heart attack in the last 6 months
- You don't have uncontrolled high blood pressure or certain advanced eye conditions like glaucoma or a detached retina
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (MK-8748) against an existing treatment (aflibercept) for people with diabetic macular edema, which causes vision loss due to swelling in the back of the eye. The goal is to see which works better to improve or protect vision.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.